OptiNose’s flagship device is a unique drug delivery system.
There’s a pretty simple idea at the heart of Pennsylvania-based biopharma firm OptiNose: plenty of perfectly good drugs just aren’t living up to their full potential, thanks to a lack of innovation in drug delivery tech.
OptiNose’s flagship device is striving to be a better mouse trap of sorts, according to the company, and has the potential to be a boon to patients suffering from chronic sinusitis—an uncomfortable inflammatory nasal condition that can make it hard to sleep and could require surgery that may not be all that effective.
